MARKET

CFRX

CFRX

ContraFect
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3189
-0.0037
-1.15%
After Hours: 0.3200 +0.0011 +0.34% 17:43 12/11 EST
OPEN
0.3200
PREV CLOSE
0.3226
HIGH
0.3400
LOW
0.3135
VOLUME
913.92K
TURNOVER
--
52 WEEK HIGH
2.180
52 WEEK LOW
0.2693
MARKET CAP
25.32M
P/E (TTM)
7.25
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CFRX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CFRX News

  • ContraFect Prices 37.15M Share Common Stock Offering At $0.27/Share
  • Benzinga.1d ago
  • ContraFect Corporation Prices Approximately $10 Million Public Offering of Common Stock and Concurrent $3 Million Private Placement of Common Stock to Pfizer
  • GlobeNewswire.1d ago
  • The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares
  • Benzinga.1d ago
  • The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares
  • Benzinga.1d ago

More

Industry

Biotechnology & Medical Research
-0.34%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About CFRX

ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapeutic protein and antibody products for the treatment of infectious diseases, including those caused by drug-resistant pathogens, particularly those treated in hospital settings. Its pipeline of lysin candidates includes CF-301, CF-302, CF-303, CF-309, CF-304, CF-305, CF-306, CF-307 and CF-308. Its other product candidate includes CF-404. Its lysin product candidate, CF-301 is developed for the treatment of Staph aureus bacteremia, including endocarditis, caused by methicillin-resistant Staph aureus and susceptible Staph aureus strains. Its product candidate, CF-404 is used for the treatment of human influenza, including seasonal and pandemic varieties. It focuses on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses.
More

Webull offers ContraFect Corp (CFRX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.